XLO
Xilio Development IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$52.53M
P/E Ratio
—
EPS
$-2.28
Beta
-0.13
52W High
$12.74
52W Low
$6.47
50-Day MA
$8.24
200-Day MA
$9.22
Dividend Yield
—
Profit Margin
-58.50%
Forward P/E
—
PEG Ratio
—
About Xilio Development Inc
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune systems of cancer patients. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $53.48M |
| Gross Profit (TTM) | $53.48M |
| EBITDA | $-40.85M |
| Operating Margin | -111.60% |
| Return on Equity | -75.20% |
| Return on Assets | -19.80% |
| Revenue/Share (TTM) | $9.25 |
| Book Value | $7.79 |
| Price-to-Book | 0.72 |
| Price-to-Sales (TTM) | 0.98 |
| EV/Revenue | 10.21 |
| EV/EBITDA | -0.11 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 331.70% |
| Shares Outstanding | $6.58M |
| Float | $3.65M |
| % Insiders | 28.58% |
| % Institutions | 53.54% |
Historical Volatility
HV 10-Day
51.23%
HV 20-Day
46.09%
HV 30-Day
60.02%
HV 60-Day
51.01%
HV Rank
—
Volatility is currently contracting
More HEALTHCARE Stocks
Data last updated: 6/13/2026